Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial

BACKGROUND: We report a first-in-human trial evaluating safety and immunogenicity of a recombinant BCG, AERAS-422, over-expressing TB antigens Ag85A, Ag85B, and Rv3407 and expressing mutant perfringolysin. METHODS: This was a randomized, double-blind, dose-escalation trial in HIV-negative, healthy a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:EBioMedicine
Autori principali: Hoft, Daniel F., Blazevic, Azra, Selimovic, Asmir, Turan, Aldin, Tennant, Jan, Abate, Getahun, Fulkerson, John, Zak, Daniel E., Walker, Robert, McClain, Bruce, Sadoff, Jerry, Scott, Judy, Shepherd, Barbara, Ishmukhamedov, Jasur, Hokey, David A., Dheenadhayalan, Veerabadran, Shankar, Smitha, Amon, Lynn, Navarro, Garnet, Podyminogin, Rebecca, Aderem, Alan, Barker, Lew, Brennan, Michael, Wallis, Robert S., Gershon, Anne A., Gershon, Michael D., Steinberg, Sharon
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4909487/
https://ncbi.nlm.nih.gov/pubmed/27322481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2016.04.010
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi